We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Venn Life Sciences Holdings Plc | LSE:VENN | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 6.85 | 6.70 | 7.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMVENN
RNS Number : 5675L
Venn Life Sciences Holdings PLC
20 July 2017
Venn Life Sciences Holdings Plc
("Venn" or the "Company" or the "Group")
Half year end update
Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, provides the following update for the six months ended 30 June 2017.
The new financial year started well with contract wins of EUR5.7m secured in January and February, as previously announced. Overall, the Company has achieved total revenues of EUR9.1m (H2 2016 EUR8.84m) for the first six months of the year. Our client and revenue mix remains well balanced with strong rates of repeat business and we have successfully delivered initial cross sales between the early and late phase client bases. We have a strong proposals book which coupled with this solid first half performance provides confidence around full year revenue expectations. We finished the first half year with a cash position of EUR2.9m (EUR1.75m as at 30 June 2016).
Enquiries:
Hot Features
Premium
Venn Life Sciences Holdings
Plc
Allan Wood - Non executive Tel: +44 7785 325898
Chairman
Tony Richardson, Chief Executive Tel: +353 154 99 341
Officer
Davy (Nominated Adviser, ESM
Adviser and Joint Broker)
Fergal Meegan / Matthew DeVere Tel: +353 1 679 6363
White (Corporate Finance)
Hybridan LLP (Co-Broker)
Claire Louise Noyce Tel: +44(0) 20 3764
2341
Walbrook PR Ltd Tel: +44(0)20 7933 8787 or venn@walbrookpr.com
Paul McManus Mob: +44(0) 7980 541
893
Lianne Cawthorne Mob: +44(0) 7584 391
303
About Venn Life Sciences:
Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTGGUGWMUPMPUB
(END) Dow Jones Newswires
July 20, 2017 02:00 ET (06:00 GMT)
1 Year Venn Life Sciences Chart |
1 Month Venn Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
